European journal of neurology · 2025
Tablet-Assisted Speech and Language Therapy for Acute Post-Stroke Aphasia: A Randomized Clinical Trial (LEXI Study).
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wischmann Johannes, Brasch Leanna, Franzen Julia, Schwierz Jennifer, Kovalenko Oksana, Gutmann Andrea, Erbert Franziska, Bußmann Luisa, Lauer Julia, Dumberger Claudia, Mandl Alexander, Mehringer Marie, Münsterer Annette, Spitzer Julia, Winterhalter Lena, Frank Vanessa, Rheinwald Marika, Lehner Katharina, Ammer Franziska, Pfahler Angelika, Lampart Stefanie, Young Charlotte, Young Peter, Goettert Barbara, Bitzan Marcella, Rinder Stephanie, Meier Oliver, Feil Katharina, Kellert Lars
Аннотация
BACKGROUND: Aphasia after acute stroke is a frequent and disabling condition, impairing communication and quality of life. We investigated whether tablet-assisted Speech and Language Therapy (SLT) using the Neolexon application is superior to standard SLT in acute stroke patients.
METHODS: In this prospective, open-label, randomized, controlled clinical trial, patients with acute post-stroke aphasia were recruited from one stroke center and two neurorehabilitation clinics in Germany. Participants were stratified by aphasia severity and randomized to tablet-assisted SLT (n = 53) or standard SLT (n = 51), initiated during inpatient care and continued in rehabilitation (30 min/Day). The primary outcome was the change in the Bielefelder Aphasia Screening (BIAS) percentile rank from baseline to 90 days. Secondary outcomes included frequency and duration of self-training.
RESULTS: From 07/2021 to 09/2024, 4097 patients were screened and 104 randomized (mean age 74.4 ± 11.2 years; 51.9% female). No significant difference in BIAS change was found at 90 days (18 vs. 14). The trial was stopped early for futility. The intervention group engaged in self-directed training more frequently (37.7% vs. 21.6%) and trained longer (10 vs. 4 h). Subgroup analyses showed benefits of tablet-assisted SLT in patients with mild (β = 15.51; 95% CI -1.67 to 32.69) and moderate aphasia (β = 23.58; 95% CI -4.48 to 51.65), and those with a National Institutes of Health Stroke Scale of less than 5 (β = 21.69; 95% CI 5.54-37.84).
CONCLUSIONS: Although underpowered to demonstrate overall superiority, tablet-assisted SLT showed potential benefits in patients with mild to moderate aphasia and less severe strokes in the acute setting.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04080817.
METHODS: In this prospective, open-label, randomized, controlled clinical trial, patients with acute post-stroke aphasia were recruited from one stroke center and two neurorehabilitation clinics in Germany. Participants were stratified by aphasia severity and randomized to tablet-assisted SLT (n = 53) or standard SLT (n = 51), initiated during inpatient care and continued in rehabilitation (30 min/Day). The primary outcome was the change in the Bielefelder Aphasia Screening (BIAS) percentile rank from baseline to 90 days. Secondary outcomes included frequency and duration of self-training.
RESULTS: From 07/2021 to 09/2024, 4097 patients were screened and 104 randomized (mean age 74.4 ± 11.2 years; 51.9% female). No significant difference in BIAS change was found at 90 days (18 vs. 14). The trial was stopped early for futility. The intervention group engaged in self-directed training more frequently (37.7% vs. 21.6%) and trained longer (10 vs. 4 h). Subgroup analyses showed benefits of tablet-assisted SLT in patients with mild (β = 15.51; 95% CI -1.67 to 32.69) and moderate aphasia (β = 23.58; 95% CI -4.48 to 51.65), and those with a National Institutes of Health Stroke Scale of less than 5 (β = 21.69; 95% CI 5.54-37.84).
CONCLUSIONS: Although underpowered to demonstrate overall superiority, tablet-assisted SLT showed potential benefits in patients with mild to moderate aphasia and less severe strokes in the acute setting.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04080817.